Yahoo · Sep 8, 2026
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:
RG
NASDAQ · RGNX
REGENXBIO Inc.
Healthcare · Biotechnology
$8.56
Down-$0.17 (-1.95%)
Updated Sep 11, 2026, 4:59 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 650.96M
- P/E ratio
- -3.74
- Dividend yield
- 0.00%
- 52-week range
- $5.46 – $15.88
- Volume
- 1.17M
- Avg. volume
- 586.76K
Price performance
RGNX price history
1M range · 20 trading sessions · Daily adjusted prices
RGNX closed at $8.56 after 20 trading sessions, down 19.70% for the selected period.
- Last close
- $8.56
- Period change
- -19.70%
- Period low
- $8.06
- Period high
- $12.02
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $8.63 | $8.79 | $8.47 | $8.56 | 1.17M |
| Sep 9, 2026 | $8.70 | $9.025 | $8.62 | $8.73 | 1.41M |
| Sep 8, 2026 | $8.95 | $8.95 | $8.60 | $8.76 | 998.96K |
| Sep 4, 2026 | $9.09 | $9.215 | $8.86 | $8.94 | 1.07M |
| Sep 3, 2026 | $9.56 | $9.56 | $9.00 | $9.20 | 839.25K |
| Sep 2, 2026 | $9.34 | $9.7075 | $9.20 | $9.60 | 866.27K |
| Sep 1, 2026 | $9.38 | $9.6162 | $9.28 | $9.32 | 783.8K |
| Aug 31, 2026 | $9.50 | $9.68 | $9.09 | $9.50 | 1.61M |
| Aug 28, 2026 | $10.00 | $10.10 | $9.212 | $9.66 | 1.75M |
| Aug 27, 2026 | $9.35 | $9.46 | $9.04 | $9.37 | 916.59K |
| Aug 26, 2026 | $8.85 | $9.43 | $8.61 | $9.38 | 1.16M |
| Aug 25, 2026 | $8.14 | $8.99 | $8.13 | $8.91 | 1.76M |
| Aug 24, 2026 | $8.29 | $8.64 | $7.77 | $8.055 | 5.45M |
| Aug 21, 2026 | $11.14 | $11.16 | $10.49 | $10.72 | 1.01M |
| Aug 20, 2026 | $11.975 | $12.08 | $11.03 | $11.06 | 947.37K |
| Aug 19, 2026 | $11.50 | $12.04 | $11.50 | $12.02 | 1.15M |
| Aug 18, 2026 | $11.13 | $11.20 | $10.73 | $11.07 | 623.93K |
| Aug 17, 2026 | $10.69 | $11.36 | $10.53 | $11.33 | 1.04M |
| Aug 14, 2026 | $10.68 | $10.86 | $10.34 | $10.765 | 792.51K |
| Aug 13, 2026 | $11.03 | $11.25 | $10.6101 | $10.66 | 805.58K |
Latest RGNX news
The latest Smart Investors Daily articles mentioning RGNX.
Stock researchCompany · Overview
RGNX research
Overview
Company profile and research snapshot.
Company profile
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $30.14
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | Baird | Outperform | — |
| Aug 25, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | Barclays | Equal-Weight | — |
| Jun 24, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 5, 2026
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome
Regenxbio Inc. (NASDAQ:RGNX) suffered another setback in its effort to bring RGX-121 to patients with Hunter syndrome. The FDA placed the experimental gene therapy on clinical hold after spinal scans identified abnormalities in five treated participants, and Reuters reported that Regenxbio shares fell more than 24% in premarket trading following the announcement. The findings add […]
Benzinga · Aug 25, 2026
HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $21
HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $23 to $21.
SeekingAlpha · Aug 25, 2026
Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity
Regenxbio (RGNX) analysis: high-volatility ârisky buyâ amid FDA hold, cash runway to 2027, and big gene therapy catalysts (AbbVie, DMD). Click here to read.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
